



AYSA

THERAPEUTICS INFUSION

RHEUMATOLOGY ORDER FORM

P: 470.395.6076 | F: 470.745.0716

PATIENT INFORMATION

Demographics attached

Patient Name: _____ DOB: _____ Phone: _____

INSURANCE INFORMATION: PLEASE ATTACH COPY OF PRESCRIPTION/MEDICAL CARD(S) (FRONT AND BACK)

MEDICAL INFORMATION

Patient Weight: _____ lbs. Patient Height: _____

Allergies: _____

Previously Failed Therapies: _____ Date: _____

Diagnosis: _____ (ICD-10)

- | | |
|--|--|
| <input type="checkbox"/> Iridocyclitic (Uveitis), Unspecified Acute and Subacute | <input type="checkbox"/> Rheumatoid Arthritis, Unspecified |
| <input type="checkbox"/> Unspecified Iridocyclitis | <input type="checkbox"/> Ankylosing Spondylitis, Unspecified |
| <input type="checkbox"/> Arthropathic Psoriasis, Unspecified | <input type="checkbox"/> Gout |
| <input type="checkbox"/> Rheumatoid Arthritis with Rheumatoid Factor, Unspecified | <input type="checkbox"/> Systemic Lupus Erythematosus |
| <input type="checkbox"/> Rheumatoid Arthritis without Rheumatoid Factor, Unspecified | <input type="checkbox"/> Other: _____ |

Premedication (if applicable)

- | | |
|---|---|
| <input type="checkbox"/> Tylenol 1000mg PO | <input type="checkbox"/> Pepcid 20mg IV |
| <input type="checkbox"/> Benadryl 25-50mg PO/IV | <input type="checkbox"/> Loratadine 10mg PO OR Cetirizine 10mg PO |
| <input type="checkbox"/> Solu-Medrol 125mg IV | <input type="checkbox"/> Other: _____ |

Clinical/Progress Notes, Labs, and Tests supporting primary diagnosis attached

Lab Orders: _____

RHEUMATOLOGY ORDERS

DRUG	DOSING	REFILL
Actemra	<input type="checkbox"/> 4mg/kg IV every 4 weeks for _____ doses, then followed by 8mg/kg every 4 weeks thereafter <input type="checkbox"/> 4mg/kg IV every 4 weeks <input type="checkbox"/> 8mg/kg IV every 4 weeks <input type="checkbox"/> Other dose: _____ mg IV every 4 weeks	
Cimzia	Initial Dose: 400mg subcutaneously at weeks 0, 2, and 4 weeks Maintenance Dose: <input type="checkbox"/> 200mg subcutaneously every 2 weeks <input type="checkbox"/> 400mg subcutaneously every 4 weeks	
Krystexxa	<input type="checkbox"/> 8mg IV in 250mL of NS IV over 120 minutes every 2 weeks *Patient will be observed 1 hour post infusion	* Serum Uric Acid required within 72 hours of infusion*
IVIg	<input type="checkbox"/> IV <input type="checkbox"/> Sub Q <input type="checkbox"/> 5% <input type="checkbox"/> 10% <input type="checkbox"/> _____ % _____ gm/kg IV divided over _____ day(s) _____ mg/kg IV divided over _____ day(s) <input type="checkbox"/> Every _____ weeks for one year or _____ one time dose	
Orencia	Orencia Dose: _____ mg IV Frequency: <input type="checkbox"/> Every 4 weeks OR <input type="checkbox"/> 0, 2, 4, weeks, and every 4 weeks thereafter	
SimponiARIA	<input type="checkbox"/> Initial Dose: 2mg/kg at weeks 0, 4, and then every 8 weeks <input type="checkbox"/> Maintenance Dose: 2mg/kg every 8 weeks	
Stelara	<input type="checkbox"/> Initial Dose: 45mg subcutaneously initially, 4 weeks later, followed by 45mg every 12 weeks <input type="checkbox"/> Maintenance Dose: 45mg subcutaneously every 12 weeks <input type="checkbox"/> Initial Dose: 90mg subcutaneously initially, 4 weeks later, followed by 90mg every 12 weeks <input type="checkbox"/> Maintenance Dose: 90mg subcutaneously every 12 weeks	
Remicade	Dose: _____ mg/kg Frequency: <input type="checkbox"/> Every _____ weeks <input type="checkbox"/> 0, 2, 6, then every 8 weeks	
Rituxan	Dose: 1000mg Frequency: <input type="checkbox"/> One time dose <input type="checkbox"/> Day 0, repeat dose in 2 weeks	

PHYSICIAN INFORMATION

By signing this form and utilizing our services, you are authorizing At Your Service Anesthesia, Inc., and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies.

Physician Signature: _____ Physician Name: _____ Date: _____ Phone: _____
Fax: _____ Contact Person: _____

ATYOURSERVICEANESTHESIA.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately. If you have received this in error, destroy the document immediately.